Stifel Nicolaus Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) had its target price lifted by Stifel Nicolaus from $200.00 to $207.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on ASND. Wedbush restated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday. Jefferies Financial Group upped their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. TD Cowen increased their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $126.51 on Friday. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The stock’s 50-day moving average is $132.30 and its two-hundred day moving average is $132.60. The stock has a market cap of $7.67 billion, a PE ratio of -15.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP increased its stake in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares during the period. Capital International Investors grew its position in shares of Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after buying an additional 10,044 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after acquiring an additional 155,971 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.